Printer Friendly

United States : FDA accepts Immune Pharma's IND application for Bertilimumab.

Immune Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its first in class, lead product candidate, Bertilimumab, to treat Bullous Pemphigoid (BP).

The approval allows the company to expand recruitment for its clinical trials.

Immune's IND application is to treat BP, an orphan autoimmune skin disease known to be related to increased eotaxin-1 levels in serum and blister fluids.

Neil Korman, MD, PhD, Professor of Dermatology, University Hospitals, Case Medical Center, Cleveland, OH, said, "An autoimmune blistering disease, Bullous Pemphigoid, has no real treatments beyond powerful anti-inflammatory medicines called corticosteroids. Yet, for patients with suppressed immune systems, steroids may not be a long-term treatment option. We believe that regulating eotaxin-1 levels may provide patients with much needed relief."

[c] 2015 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).

COPYRIGHT 2015 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Nov 10, 2015
Words:145
Previous Article:United States : McAfee Labs Threat Predictions Preview Cyber Threat Landscape for 2016 and Beyond.
Next Article:United States : Sophos' new technology synchronizes threat intelligence and automation across endpoint and network levels.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters